260
Participants
Start Date
April 1, 2006
Primary Completion Date
February 1, 2007
Study Completion Date
May 1, 2007
CC-10004
20 mg CC-10004 taken 1 time per day for 12 weeks
CC-10004
20 mg of CC-10004 taken 2 times per day for 12 weeks
Placebo
matching placebo taken either 1 or 2 times per day for 12 weeks
Division of Dermatology and Cutaneous Science, Edmonton
Division of Dermatology, Vancouver
Department of Dermatology, Brno
Department of Dermatology, Hradec Králové
Department of Dermatovererology, Olomouc
Department of Dermatovererology, Prague
Depart of Dermatology, Ústí nad Labem
Celgene Clinical Site, Ausburg
Celgene Clinical Site, Berlin
Department of Dermatologie and Venerology, Dresden
Department of Dermatology and Venerology, Frankfurt am Main
Celgene Clinical Site, Hamburg
Celgene Clinical Site, Heidelberg
Celgene Clinical Site, Herborn
Celgene Clinical Site, Homburg
Celgene Clinical Site, Leipzig
Celgene Clinical Site, Mannheim
Celgene Clinical Site, Münster
Celgene Clinical Site, Salzwedel
Celgene Clinical Site, Schwerin
Celgene Clinical Site, Wiesbaden
Celgene Clinical Site, Würzburg
Duronder C.P. Inc, Moncton
Eastern Canada Cutaneous Research Associates, Halifax
Ultranova Skincare, Barrie
Dermatrials Research, Hamilton
The Lynde Center for Dermatology, Markham
K. Papp Clinical Research, Waterloo
North Bay Dermatology Centre, North Bay
Innovaderm, Montreal
Dr Yves Poulin, Québec
Lead Sponsor
Amgen
INDUSTRY